Actively Recruiting
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Led by Nanjing Legend Biotech Co. · Updated on 2025-12-29
35
Participants Needed
4
Research Sites
218 weeks
Total Duration
On this page
Sponsors
N
Nanjing Legend Biotech Co.
Lead Sponsor
I
Institute of Hematology & Blood Diseases Hospital, China
Collaborating Sponsor
AI-Summary
What this Trial Is About
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple myeloma(Investigator-initiated Study).
CONDITIONS
Official Title
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate in clinical research
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Confirmed initial diagnosis of multiple myeloma according to IMWG criteria
- Presence of measurable lesions
- Previous treatment with one proteasome inhibitor, one immunomodulatory drug, and a CD38 monoclonal antibody
- Received at least three prior lines of multiple myeloma therapy, each with at least one complete cycle, unless disease progression was documented
- Expected survival of at least 3 months
- Clinical laboratory values meeting screening criteria
You will not qualify if you...
- Prior therapy targeting FcRH5
- Previous antineoplastic therapy meeting exclusion criteria before apheresis
- Diagnosis of plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at screening
- Positive test for HBsAg, HBV DNA, HCV antibody, HCV RNA, or HIV antibody
- History of life-threatening allergic or hypersensitivity reactions to CAR-T cell products or their components including DMSO
- Presence of serious underlying diseases
- Females who are pregnant, breastfeeding, or planning pregnancy during or within one year after study treatment
- Participation in other clinical studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Beijing Boren Hospital
Beijing, China
Not Yet Recruiting
2
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Actively Recruiting
3
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Actively Recruiting
4
Wuhan Union Hospital
Wuhan, China
Actively Recruiting
Research Team
T
Tingting Wang
CONTACT
J
Jianling Yao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here